Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

peptide receptor radionuclide therapy

  • Impact of Single-Time-Point Estimates of <sup>177</sup>Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
    You have access
    Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
    Alexandre Chicheportiche, Moshe Sason, Mahmoud Zidan, Jeremy Godefroy, Yodphat Krausz, David J. Gross, Simona Grozinsky-Glasberg and Simona Ben-Haim
    Journal of Nuclear Medicine July 27, 2023, jnumed.122.264923; DOI: https://doi.org/10.2967/jnumed.122.264923
  • Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden
    You have access
    Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden
    Denise A. Gococo-Benore, Justin Kuhlman, Ephraim E. Parent, Akash Sharma, Joseph Accurso, Ming Yang, Ayse Tuba Kendi, Geoff Johnson, Mohamad Bassam Sonbol, Timothy Hobday, Thorvardur R. Halfdanarson and Jason Starr
    Journal of Nuclear Medicine June 1, 2023, 64 (6) 880-884; DOI: https://doi.org/10.2967/jnumed.122.264533
  • Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients
    You have access
    Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Noémie S. Minczeles, Wouter W. de Herder, Richard A. Feelders, Frederik A. Verburg, Johannes Hofland and Tessa Brabander
    Journal of Nuclear Medicine January 1, 2023, 64 (1) 40-46; DOI: https://doi.org/10.2967/jnumed.122.263856
  • Safety of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    You have access
    Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    Shahad Alsadik, Gopinath Gnanasegaran, Luohai Chen, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin and Shaunak Navalkissoor
    Journal of Nuclear Medicine October 1, 2022, 63 (10) 1503-1508; DOI: https://doi.org/10.2967/jnumed.121.263056
  • Efficacy and Safety of <sup>177</sup>Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
    You have access
    Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
    Lamiaa Zidan, Amir Iravani, Kira Oleinikov, Simona Ben-Haim, David J. Gross, Amichay Meirovitz, Ophra Maimon, Tim Akhurst, Michael Michael, Rodney J. Hicks, Simona Grozinsky-Glasberg and Grace Kong
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 218-225; DOI: https://doi.org/10.2967/jnumed.120.260760
  • Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
    Open Access
    Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
    Giulia Tamborino, Julie Nonnekens, Marijke De Saint-Hubert, Lara Struelens, Danny Feijtel, Marion de Jong and Mark W. Konijnenberg
    Journal of Nuclear Medicine January 1, 2022, 63 (1) 100-107; DOI: https://doi.org/10.2967/jnumed.121.262122
  • Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant <sup>177</sup>Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors
    You have access
    Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors
    Rahul V. Parghane, Manish Bhandare, Vikram Chaudhari, Vikas Ostwal, Anant Ramaswamy, Sanjay Talole, Shailesh V. Shrikhande and Sandip Basu
    Journal of Nuclear Medicine November 1, 2021, 62 (11) 1558-1563; DOI: https://doi.org/10.2967/jnumed.120.258772
  • You have access
    Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
    Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512
  • You have access
    Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma
    Jorge A. Carrasquillo, Clara C. Chen, Abhishek Jha, Karel Pacak, Daniel A. Pryma and Frank I. Lin
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1192-1199; DOI: https://doi.org/10.2967/jnumed.120.259697
  • You have access
    A Rapid and Safe Infusion Protocol for 177Lu Peptide Receptor Radionuclide Therapy
    Sander C. Ebbers, Maarten W. Barentsz, Bart de Keizer, Gerard C. Krijger, Marnix G.E.H. Lam and Arthur J.A.T. Braat
    Journal of Nuclear Medicine June 1, 2021, 62 (6) 816-822; DOI: https://doi.org/10.2967/jnumed.120.252494

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire